Smith-Lemli-Opitz Syndrome
14
1
1
9
Key Insights
Highlights
Success Rate
82% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
14.3%
2 terminated out of 14 trials
81.8%
-4.7% vs benchmark
0%
0 trials in Phase 3/4
56%
5 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (14)
Study of Smith-Lemli-Opitz Syndrome
Functional Near-Infrared Spectroscopy (fNIRS) Combined With Diffuse Correlation Spectroscopy (DCS) in Neurocognitive Disease as Compared to Healthy Neurotypical Controls
Baby Detect : Genomic Newborn Screening
Early Check: Expanded Screening in Newborns
Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)
Smith-Lemli-Opitz Syndrome and Cholic Acid
SLOS: The Effect of Simvastatin in Patients Receiving Cholesterol Supplementation
Sterol and Isoprenoid Disease Research Consortium: Smith-Lemli-Opitz Syndrome
Treatment of the Cholesterol Defect in Smith-Lemli-Opitz Syndrome
Short-term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome
Simvastatin Therapy in Smith-Lemli-Opitz Syndrome
Estimation of the Carrier Frequency and Incidence of Smith-Lemli-Opitz Syndrome in African Americans
Prenatal Screening For Smith-Lemli-Opitz Syndrome
Phase II Study of Dietary Cholesterol for Smith-Lemli-Opitz Syndrome